Cell and Gene Therapy

NeuExcell Therapeutics Announces Successful Dosing of First Patient by NeuroD1 Gene Therapy

Published March. 26. 2024
CGT Banner - NeuExcell

NeuExcell Therapeutics has achieved a significant milestone by successfully dosing the first patient with their groundbreaking NeuroD1 gene therapy product, NXL-004, aimed at treating malignant glioma, a highly aggressive form of brain cancer. Led by Professor Yulun Huang and his team in China, this investigator-initiated trial marks the first clinical use of AAV-NeuroD1 gene therapy worldwide for glioblastoma patients. NXL-004, based on NeuExcell’s innovative in vivo trans-differentiation technology, seeks to inhibit tumor cell proliferation and promote their transformation into neural cells, offering a potentially promising treatment avenue with minimal side effects on healthy brain cells. The trial’s completion of the first patient dosing signifies a significant step forward in addressing unmet medical needs in glioblastoma treatment, with the company committed to closely monitoring safety and efficacy throughout the study. This milestone underscores NeuExcell’s dedication to pioneering game-changing treatments for severe neurological disorders using in vivo neural regenerative therapies

https://www.prnewswire.com/news-releases/neuexcell-therapeutics-announces-successful-dosing-of-first-patient-by-neurod1-gene-therapy-302096579.html

Get the free newsletter

Subscribe to IMAPAC for top news, trends & analysis

Cell and Gene Therapy World Summit Brochure

    Contact Form


    IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.

    Download Brochure Sample

      Contact Form


      IMAPAC requires your contact information to reach out to you about our products and services. You can unsubscribe from these communications at any time. For details on how to unsubscribe and to learn more about our privacy practices and our commitment to protecting your privacy, please review our Privacy Policy.